Linda Zhu

Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis

Melinda Gooderham, Seth Forman, Robert Bissonnette et al. · JAMA Dermatology · 2019 · 237 citations · Full text

Medicine, Dermatology, Pharmacology +11

A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results

Brett King, Emma Guttman‐Yassky, Elena Peeva et al. · Journal of the American Academy of Dermatology · 2021 · 193 citations · Full text

Medicine, Dermatology, Pharmacology +15

Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers

Emma Guttman‐Yassky, Ana B. Pavel, Aisleen Diaz et al. · Journal of Allergy and Clinical Immunology · 2021 · 96 citations · Full text

Medicine, Dermatology, Pharmacology +16

Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial

Elena Peeva, Emma Guttman‐Yassky, Anindita Banerjee et al. · Journal of the American Academy of Dermatology · 2021 · 42 citations · Full text

Medicine, Dermatology, Pharmacology +13

Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover Open-Label Extension of the ALLEGRO Phase 2a Trial

Brett King, Emma Guttman‐Yassky, Elena Peeva et al. · JID Innovations · 2022 · 24 citations · Full text

Medicine, Oncology, Pharmacology +13